[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:neuromyelitis-optica":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":155,"states":164},"Neuromyelitis Optica",23,17,[8,16,23,30,36,42,48,54,60,66,72,78,84,90,96,102,108,114,121,128,135,141,149],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT05549258","Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder",[12],"Phase 2","RECRUITING","2026-08-26T02:16:26.411851Z","2026-05-05T02:43:29.583704Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT05199688","A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)",[20],"Phase 3","2026-08-26T02:17:29.353236Z","2026-05-05T02:43:27.078519Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT06680037","A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders",[27],"Phase 1","2026-08-26T02:19:12.219640Z","2026-07-05T05:32:16.768710Z",{"nct_id":31,"title":32,"phases":33,"status":13,"updated_at":34,"content_modified":35},"NCT06453694","Efgartigimod for the Treatment of Acute Optic Neuritis",[12],"2026-08-26T02:19:08.084946Z","2026-05-05T02:43:28.743664Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT03011541","Stem Cell Ophthalmology Treatment Study II",[],"2026-08-26T02:17:33.002248Z","2026-05-05T02:43:29.077392Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":46,"content_modified":47},"NCT06398158","Study of the Clinical and Radiological Impact of Ravulizumab in People With Neuromyelitis Optica Spectrum Disorder",[],"2026-08-26T02:16:38.897933Z","2026-05-13T02:55:06.488239Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":52,"content_modified":53},"NCT05966467","Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies",[],"2026-08-26T02:16:09.452956Z","2026-05-13T02:55:06.396826Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":58,"content_modified":59},"NCT05909761","Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregnancy",[],"2026-08-26T02:16:14.341106Z","2026-05-13T02:55:06.392336Z",{"nct_id":61,"title":62,"phases":63,"status":13,"updated_at":64,"content_modified":65},"NCT05982925","Longitudinal Cortical Demyelination in Multiple Sclerosis and Related Disorders",[],"2026-08-26T02:15:20.225313Z","2026-06-16T05:54:08.094888Z",{"nct_id":67,"title":68,"phases":69,"status":13,"updated_at":70,"content_modified":71},"NCT06312644","Study of Ultomiris® (Ravulizumab) Safety in Pregnancy",[],"2026-08-26T02:15:47.754948Z","2026-05-13T02:55:06.435129Z",{"nct_id":73,"title":74,"phases":75,"status":13,"updated_at":76,"content_modified":77},"NCT05004493","Biorepository and Registry for Plasma Exchange Patients",[],"2026-08-26T02:18:18.766496Z","2026-05-13T02:55:06.276731Z",{"nct_id":79,"title":80,"phases":81,"status":13,"updated_at":82,"content_modified":83},"NCT07220915","Supporting Weak Immune System During Autoimmune Therapy: Testing Panzyga to Prevent Infections",[20],"2026-08-26T02:17:05.997056Z","2026-07-24T01:27:14.901588Z",{"nct_id":85,"title":86,"phases":87,"status":13,"updated_at":88,"content_modified":89},"NCT06940323","Pregnancy Registry, Infants, Serum\u002FMilk Analysis (PRISMA)",[],"2026-08-26T02:19:18.331180Z","2026-05-13T02:55:06.592968Z",{"nct_id":91,"title":92,"phases":93,"status":13,"updated_at":94,"content_modified":95},"NCT05204459","MS-ResearchBiomarkerS",[],"2026-08-26T02:19:27.519777Z","2026-05-13T02:55:06.295412Z",{"nct_id":97,"title":98,"phases":99,"status":13,"updated_at":100,"content_modified":101},"NCT05566769","Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD",[],"2026-08-26T02:18:08.005333Z","2026-05-05T02:43:29.074153Z",{"nct_id":103,"title":104,"phases":105,"status":13,"updated_at":106,"content_modified":107},"NCT06780709","Impact of a Structured Wellness Behavioral Intervention on Quality of Life in NMOSD",[],"2026-08-26T02:17:22.949982Z","2026-05-05T02:43:28.496192Z",{"nct_id":109,"title":110,"phases":111,"status":13,"updated_at":112,"content_modified":113},"NCT06860932","A Palliative Care Model Impact on Knowledge and Attitudes",[],"2026-08-26T02:16:10.529598Z","2026-05-05T02:43:29.045656Z",{"nct_id":115,"title":116,"phases":117,"status":118,"updated_at":119,"content_modified":120},"NCT07573332","A Safety and Tolerability Study of CC- 97540 (BMS-086353) in Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Patients",[27],"NOT_YET_RECRUITING","2026-08-26T02:16:24.970704Z","2026-05-13T02:55:06.779291Z",{"nct_id":122,"title":123,"phases":124,"status":118,"updated_at":126,"content_modified":127},"NCT07010302","Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSD",[125],"Phase 4","2026-08-26T02:15:57.572488Z","2026-05-05T02:43:28.965894Z",{"nct_id":129,"title":130,"phases":131,"status":132,"updated_at":133,"content_modified":134},"NCT04886492","CorEvitas SPHERES (Synergy of Prospective Health & Experimental Research for Emerging Solutions) Registry for Neuromyelitis Optica Spectrum Disorder (NMOSD)",[],"ENROLLING_BY_INVITATION","2026-08-26T02:18:39.640967Z","2026-07-05T18:42:10.714729Z",{"nct_id":136,"title":137,"phases":138,"status":132,"updated_at":139,"content_modified":140},"NCT06374264","Acceptability and Safety of MR-C-014 in Persons With Neuromyelitis Optica Spectrum Disorder",[],"2026-08-26T02:16:56.877406Z","2026-06-16T05:54:07.750015Z",{"nct_id":142,"title":143,"phases":144,"status":146,"updated_at":147,"content_modified":148},"NCT05346354","Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD",[145],"Phase 2\u002FPhase 3","ACTIVE_NOT_RECRUITING","2026-08-03T03:14:40.336483Z","2026-05-05T02:43:27.415428Z",{"nct_id":150,"title":151,"phases":152,"status":146,"updated_at":153,"content_modified":154},"NCT06816004","Noninvasive Vagal Nerve Stimulation",[],"2026-08-03T02:45:55.777792Z","2026-05-05T02:43:27.950216Z",[156,160],{"biomarker":157,"count":158,"slug":159},"AQP4 Gene",5,"aqp4-gene",{"biomarker":161,"count":162,"slug":163},"AQP4-IgG",4,"aqp4-igg",[165,169,172,175,178,182],{"state":166,"count":167,"slug":168},"Massachusetts",9,"massachusetts",{"state":170,"count":158,"slug":171},"California","california",{"state":173,"count":158,"slug":174},"New York","new-york",{"state":176,"count":162,"slug":177},"Texas","texas",{"state":179,"count":180,"slug":181},"Florida",3,"florida",{"state":183,"count":180,"slug":184},"North Carolina","north-carolina"]